AI Stock Monitor
JNJ - Johnson & Johnson
Johnson & Johnson is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Pharmaceuticals · Medical Devices · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NYSE · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
70
/100
Price History
JNJ chart
AI-Assisted Chart Analysis
Johnson & Johnson technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Mixed trend: the latest level is below its 20-period average, without full long-term confirmation.
RSI is 56, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 265.58. A break below 247.02 invalidates the near-term support setup.
The first resistance/watch zone is 278.43. A confirmed break above 278.43 supports continuation.
Annualized realized volatility is +24.4%. Maximum lookback drawdown is -7.6%, from a high-water mark of 267.24 to 247.02.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported JNJ at 269.47 USD; the latest daily move fell -0.19%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified -0.19% daily move is current market context for Johnson & Johnson.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The current evidence-grounded AI read is bearish.
- Evidence: Recent regulatory progress and strategic divestitures align with the company's goal of focusing on high-margin pharmaceutical and medtech segments.
- Uncertainty: While the company maintains a strong dividend profile, investors are watching for how effectively these pipeline assets can drive future revenue growth against competitive pressures.
- Watch: The current evidence does not suggest a material change in the financial trajectory, and the thesis remains focused on the balance between legacy cash flows and new product launches.
Key Risks
- Regulatory setbacks or delays in the approval of key pipeline assets could hinder revenue growth targets and weaken the long-term thesis.
- Increased competition in the pharmaceutical and medtech markets may pressure margins and market share for established products.
- Litigation or legal liabilities remain a persistent overhang that could impact the balance sheet and capital allocation flexibility.
- Failure to successfully integrate or derive value from external partnerships could result in inefficient capital deployment.
Upcoming Catalysts
- Future earnings reports and management guidance updates will be the primary indicators of operational success and margin health.
- Clinical trial data readouts for late-stage pipeline candidates will determine the long-term revenue growth trajectory.
- Further strategic portfolio adjustments or M&A activity could signal management's confidence in capital deployment and focus.
- Updates on the commercial launch of newly approved products will confirm the efficacy of the company's go-to-market strategy.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceReportedJ&J Gains as Caplyta Opens a Mania Expansion Path · Published 2026-09-22 00:06:17Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedJohnson & Johnson (JNJ) Latest Press Releases & Corporate News - Yahoo Finance - ca.finance.yahoo.com · Published 2026-09-22 00:06:17Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedPsoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight · Published 2026-09-22 00:06:17Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedNovo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations · Published 2026-09-22 00:06:17Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedHow Far Could ISRG Stock Bounce From Here? · Published 2026-09-22 00:06:17Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.